MilliporeSigma’s Life Science business has closed its acquisition of Mirus Bio for approximately $600 million following regulatory clearances and the fulfillment of other customary closing conditions.
 
The acquisition is a strategic step towards the company’s ambition to offer solutions for every step of viral vector manufacturing. It also reinforces the company’s commitment to supporting customers in advancing cell and gene therapies from preclinical through commercial production.
 
“Novel modalities like cell and gene therapies offer tremendous potential for bringing new curative treatments to patients,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. “Mirus Bio’s advanced technology, combined with our bioprocessing expertise and broad portfolio, will enable us to deliver integrated solutions across the viral vector value chain and help meet the growing demand for these life-saving therapies.”
 
Mirus Bio specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN. These reagents play a critical role in the production of viral vector-based gene therapies. The addition of Mirus Bio’s leading transfection reagents strengthens MilliporeSigma’s upstream portfolio and allows for an integrated viral vector manufacturing offering.

More Pharma Acquisitions